
jack Stone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4590046/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health, 2017, 5, e1192-e1207.	6.3	1,020
2	Public health and international drug policy. Lancet, The, 2016, 387, 1427-1480.	13.7	460
3	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet, The, 2019, 394, 1560-1579.	13.7	404
4	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet, The, 2016, 388, 1228-1248.	13.7	213
5	Global, regional, and countryâ€level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	3.3	178
6	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1397-1409.	9.1	147
7	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health, The, 2021, 6, e309-e323.	10.0	99
8	Prevalence and burden of HBV coâ€infection among people living with HIV: A global systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2020, 27, 294-315.	2.0	81
9	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction, 2017, 112, 1302-1314.	3.3	80
10	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. International Journal of Drug Policy, 2019, 73, 172-184.	3.3	67
11	The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Medicine, 2015, 13, 198.	5.5	54
12	The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?. PLoS ONE, 2016, 11, e0156213.	2.5	41
13	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. American Journal of Epidemiology, 2019, 188, 1539-1551.	3.4	29
14	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. Journal of Infectious Diseases, 2019, 220, 78-90.	4.0	29
15	Estimating the contribution of key populations towards HIV transmission in South Africa. Journal of the International AIDS Society, 2021, 24, e25650.	3.0	28
16	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. International Journal of Drug Policy, 2020, 76, 102619.	3.3	21
17	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. International Journal of Drug Policy, 2020, 77, 102656.	3.3	20
18	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. Lancet Psychiatry,the, 2021, 8, 301-309.	7.4	20

JACK STONE

#	Article	IF	CITATIONS
19	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. The Lancet Global Health, 2020, 8, e76-e91.	6.3	19
20	Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. Lancet HIV,the, 2022, 9, e42-e53.	4.7	18
21	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. International Journal of Drug Policy, 2020, 84, 102866.	3.3	17
22	Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. International Journal of Drug Policy, 2021, 88, 102707.	3.3	14
23	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. Lancet Public Health, The, 2022, 7, e136-e145.	10.0	14
24	Modeling the populationâ€level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. Addiction, 2022, 117, 1338-1352.	3.3	11
25	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. The Lancet Gastroenterology and Hepatology, 2022, 7, 353-366.	8.1	10
26	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP Treatment as Prevention Study in Prisons. Hepatology, 2021, 74, 2366-2379.	7.3	9
27	Has resourcing of nonâ€governmental harmâ€reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bioâ€behavioural surveys. Journal of the International AIDS Society, 2020, 23, e25608.	3.0	8
28	Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison. International Journal of Drug Policy, 2021, 96, 103394.	3.3	8
29	Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. AIDS and Behavior, 2021, 25, 3814-3827.	2.7	7
30	A crossâ€sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention. Health Science Reports, 2022, 5, .	1.5	7
31	Is contact between men who have sex with men and nonâ€governmental organizations providing harm reduction associated with improved HIV outcomes?. HIV Medicine, 2021, 22, 262-272.	2.2	6
32	An intensive model of care for hepatitis C virus screening and treatment with directâ€acting antivirals in people who inject drugs in Nairobi, Kenya: a modelâ€based costâ€effectiveness analysis. Addiction, 2022, 117, 411-424.	3.3	6
33	Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya. Journal of Viral Hepatitis, 2022, 29, 691-694.	2.0	6
34	Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. Journal of the International AIDS Society, 2021, 24, e25817.	3.0	5
35	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. Eurosurveillance, 2021, 26, .	7.0	4
36	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. Drug and Alcohol Dependence, 2020, 209, 107899.	3.2	3

#	Article	IF	CITATIONS
37	Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. International Journal of Drug Policy, 2021, 96, 103419.	3.3	2